tradingkey.logo

Apogee Therapeutics Inc

APGE
View Detailed Chart

37.870USD

+0.930+2.52%
Close 08/26, 16:00ETQuotes delayed by 15 min
2.22BMarket Cap
LossP/E TTM

Apogee Therapeutics Inc

37.870

+0.930+2.52%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.52%

5 Days

+4.01%

1 Month

-7.23%

6 Months

+21.85%

Year to Date

-16.40%

1 Year

-20.12%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 9 analysts
STRONG BUY
Current Rating
96.750
Target Price
161.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Apogee Therapeutics Inc
APGE
9
CRISPR Therapeutics AG
CRSP
29
Ionis Pharmaceuticals Inc
IONS
27
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
27
IQVIA Holdings Inc
IQV
25
1
2
3
...
111

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(4)
Neutral(4)
Buy(5)
Indicators
Sell(1)
Neutral(4)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.436
Neutral
RSI(14)
50.821
Neutral
STOCH(KDJ)(9,3,3)
61.667
Neutral
ATR(14)
1.626
High Vlolatility
CCI(14)
64.592
Neutral
Williams %R
22.233
Buy
TRIX(12,20)
-0.258
Sell
StochRSI(14)
84.603
Buy
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
37.090
Buy
MA10
37.153
Buy
MA20
36.989
Buy
MA50
39.263
Sell
MA100
38.224
Sell
MA200
40.262
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Ticker SymbolAPGE
CompanyApogee Therapeutics Inc
CEODr. Michael Henderson, M.D.
Websitehttps://apogeetherapeutics.com/
KeyAI